• Explore /
  • Poster
  • / Subcutaneous amivantamab and lazertinib as first-line treatment in patients with <em>EGFR</em>-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.

Subcutaneous amivantamab and lazertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Results from the phase 2 PALOMA-2 study.

Abstract Poster

Authors

Sun Min Lim

Sun Min Lim

Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea

Sun Min Lim , Jiunn-Liang Tan , Josiane Mourão Dias , Pei Jye Voon , Soon Hin How , Xiangdong Zhou , Hailin Xiong , Bartomeu Massuti , Louise C. Medley , Misako Nagasaka , David Vicente , Nicolas Girard , Achim Rittmeyer , Dana-Adriana Botesteanu , Ali Alhadab , Janine M. Mahoney , Jie Zhang , Joshua Michael Bauml , Mahadi Baig , Susan Combs Scott

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT05498428

Citation

J Clin Oncol 42, 2024 (suppl 17; abstr LBA8612)

DOI

10.1200/JCO.2024.42.17_suppl.LBA8612

Abstract #

LBA8612

Poster Bd #

476

Abstract Disclosures

Similar Posters

First Author: Nicolas Girard

First Author: Se-Hoon Lee

First Author: Pasi A. Janne

First Author: Jonathan W. Goldman